The Michigan Collaborative for Type 2 Diabetes (MCT2D) seeks to engage and empower medical providers across the state to accelerated dissemination and implementation of evidence-based strategies to prevent or slow disease progression of Type 2 Diabetes.
Rather than simply focusing on optimizing HbA1c as the disease progresses over a patient’s lifetime, the goal will be to support providers to deliver high quality behavioral and medical treatment to prevent, slow or reverse the course of the disease.
Support for MCT2D provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.
